Research Topics
Genomes and Genes | Adilia HormigoSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Nonconvulsive status epilepticus in patients with cancer: imaging abnormalitiesAdilia Hormigo
Department of Neurology, Memorial Sloan Kettering Cancer Center, and Weill Medical College of Cornell University, New York, NY 10021, USA
Arch Neurol 61:362-5. 2004..Convulsive status epilepticus may cause reversible neuroimaging abnormalities. These cortical changes have been reported rarely in association with nonconvulsive status epilepticus...- Ocular presentation of primary central nervous system lymphoma: diagnosis and treatmentAdilia Hormigo
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Br J Haematol 126:202-8. 2004..Patients whose ocular disease was identified and treated before CNS progression had a significantly improved survival... - YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomasAdilia Hormigo
Clinical Laboratories, Neurosurgical Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Clin Cancer Res 12:5698-704. 2006..We obtained prospective longitudinal serum samples from patients with gliomas to determine whether YKL-40 or MMP-9 could be used as serum markers... 
Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomasFabio M Iwamoto
The Brain Tumor Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Neuro Oncol 13:1244-51. 2011..4, P< .0001). Longitudinal increases in serum YKL-40 are associated with increased risk of death in patients with glioblastomas and anaplastic gliomas. YKL-40 is also a putative indicator of disease status in these patients...
Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomasFabio M Iwamoto
The Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Neurooncol 105:607-12. 2011..Changes in serum MMP-9 were not associated with survival in the anaplastic glioma cohort. Serum MMP-9 showed no utility in determining glioma disease status and was not a clinically relevant prognostic marker of survival...- YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphomaAndreas F Hottinger
Brain Tumor Center, New York, NY, USA
Ann Neurol 70:163-9. 2011..To evaluate YKL-40 and MMP-9 proteins as tumor biomarkers in serum samples from patients with primary central nervous system lymphoma (PCNSL)... - Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastomaJennifer L Clarke
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY10065, USA
J Clin Oncol 27:3861-7. 2009..The goal of this randomized phase II study was to evaluate two different temozolomide regimens in the adjuvant treatment of newly diagnosed GBM... - Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant gliomaAntonio Omuro
Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Neuro Oncol 15:242-50. 2013..In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedule in the treatment of recurrent malignant gliomas (MGs)... - Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomasFabio M Iwamoto
Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Neurooncol 88:293-8. 2008..To assess the frequency of chromosomes 1p and 19q deletions in gliomas and to correlate 1p deletion with prognosis in patients with grade 2 and grade 3 gliomas independently of histologic subtype... - Treatment of primary central nervous system lymphomaLisa M DeAngelis
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Semin Oncol 31:684-92. 2004..Consequently, the role of radiotherapy remains to be clarified in newly diagnosed younger patients with PCNSL... - Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in miceSergey V Shmelkov
1 Howard Hughes Medical Institute, Ansary Stem Cell Institute and Department of Genetic Medicine, Weill Cornell Medical College, New York, New York, USA 2 These authors contributed equally to this work
Nat Med 16:598-602, 1p following 602. 2010..Thus, our studies identify Slitrk5 as an essential molecule at corticostriatal synapses and provide a new mouse model of OCD-like behaviors... - Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkersAdilia Hormigo
Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Cancer Cell 11:6-8. 2007.... - Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic reviewElena Pentsova
Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
J Neurooncol 106:15-21. 2012.... - A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastasesFabio M Iwamoto
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, 10021, USA
J Neurooncol 87:85-90. 2008..To investigate the efficacy and safety of the combination of vinorelbine and intensive temozolomide for recurrent or progressive brain metastases from solid tumors... - Primary ocular lymphoma: clinical features, diagnosis, and treatmentAdilia Hormigo
Department of Neurology, New York Presbyterian Hospital and Weill College of Medicine of Cornell University, New York, USA
Clin Lymphoma 4:22-9. 2003..The current treatment options are discussed. Although advances have been made, the optimal treatment for primary ocular lymphoma remains to be identified.. - CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumorsSergey V Shmelkov
Howard Hughes Medical Institute, Ansary Center for Stem Cell Therapeutics, and Department of Genetic Medicine, Weill Medical College of Cornell University, New York, New York, USA
J Clin Invest 118:2111-20. 2008.... - Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphomaIgor T Gavrilovic
Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 24:4570-4. 2006..For older patients, it appears to be reasonable to defer whole brain radiotherapy in an effort to minimize treatment-related neurotoxicity...